|
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical research trials and Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma clinical trial. Human subjects often receive the most effective healthcare possible for their Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma  Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
For Condition: stage 3 melanoma,stage 1 melanoma,Recurrent Melanoma,stage 2 melanoma
Status: Recruiting
Sponsor(s): North Central Cancer Treatment Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of adjuvant radiation therapy in treating patients who have resecteddesmoplastic melanoma.
Details: OBJECTIVES: - Determine the recurrence rates of patients with desmoplastic melanoma treated with adjuvant radiotherapy after surgical resection. - Determine the disease-free and overall survival of patients treated with this regimen. - Determine the immediate and long-term morbidity of patients treated with this regimen. OUTLINE: This is a multicenter study. Within 8 weeks after surgical resection, patients undergo radiotherapy twice weekly over 2.5 weeks in the absence of unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed desmoplastic melanoma - Locally recurrent OR at least 1 mm in depth - Recurrent tumor is defined as a tumor found no more than 2 cm from the previous excision or within the surgical bed (which includes the extent of previous skin flaps) - Disease resected using standard wide resection or Moh's surgery - Histologically negative margins - Tumors on proximal extremities must have a 2 cm negative margin - Tumors on the head or neck or distal extremities may have margins less than 2 cm provided they are negative - No melanoma with focally desmoplastic features, in which the desmoplastic melanoma is not the predominant histologic pattern of the tumor - No nondesmoplastic neurotropic or nondesmoplastic spindle cell melanoma - No evidence of metastatic disease (local nodal disease allowed) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 1 year Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No nonhealing surgical wound - No active infection at the surgical site PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent adjuvant immunotherapy Chemotherapy - No concurrent adjuvant chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy to the focused site of this study Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BarbaraPockaj, Study Chair, Mayo Clinic Scottsdale
CCOP - Wichita *Recruiting*
Wichita, Kansas, 67214-3882
United States
Recruiting Shaker Dakhil 316-268-5784
Mayo Clinic Cancer Center *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Steven Alberts 507-284-2511
CCOP - Sioux Community Cancer Consortium *Recruiting*
Sioux Falls, South Dakota, 57104
United States
Recruiting Loren Tschetter 605-328-8044
CCOP - Cedar Rapids Oncology Project *Recruiting*
Cedar Rapids, Iowa, 52403-1206
United States
Recruiting Martin Wiesenfeld 319-363-8303
Rapid City Regional Hospital *Recruiting*
Rapid City, South Dakota, 57709
United States
Recruiting Larry Ebbert 605-341-8704
CCOP - Dayton *Recruiting*
Dayton, Ohio, 45429
United States
Recruiting Howard Gross 937-395-8678
Medcenter One Health System *Recruiting*
Bismark, North Dakota, 58501-5505
United States
Recruiting Edward Wos 701-323-5741
CCOP - Mayo Clinic Scottsdale Oncology Program *Recruiting*
Scottsdale, Arizona, 85259-5404
United States
Recruiting Barbara Pockaj 480-301-8000
Mayo Clinic *Recruiting*
Jacksonville, Florida, 32224
United States
Recruiting Edith Perez 904-953-0118
CCOP - Iowa Oncology Research Association *Recruiting*
Des Moines, Iowa, 50309-1016
United States
Recruiting Roscoe Morton 515-244-7586
Siouxland Hematology-Oncology *Recruiting*
Sioux City, Iowa, 51101-1733
United States
Recruiting Donald Wender 712-252-0088
CCOP - Carle Cancer Center *Recruiting*
Urbana, Illinois, 61801
United States
Recruiting Kendrith Rowland 217-383-4083
Additional Information:
Study ID Numbers: CDR0000301633; NCCTG-N0275
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00060333
Other Stage 3 Melanoma Studies:
1. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
2. Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
3. Vaccine Therapy in Treating Patients With Melanoma
4. Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
5. Vaccine Therapy in Treating Patients With Stage II or Stage III Melanoma That Has Been Surgically Removed
Related Studies:
Other stage 3 melanoma Clinical Trials
Other Kansas Clinical Trials
Other Wichita Clinical Trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
|
|
|
|
|
|
|
|
